These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 3487184)
1. [Alpha interferon in the therapy of cutaneous T cell lymphomas]. Lang MH; Altmeyer P; Lodemann E; Holzmann H Z Hautkr; 1986 May; 61(9):599-608. PubMed ID: 3487184 [TBL] [Abstract][Full Text] [Related]
2. Cutaneous T cell lymphomas: mycosis fungoides, Sézary syndrome and lymphomatoid papulosis--Part I. Safai B Clin Bull; 1977; 7(3):91-7. PubMed ID: 308870 [No Abstract] [Full Text] [Related]
5. [Current therapy concepts in cutaneous T-cell lymphomas]. Nestle FO; Häffner AC; Schmid MH; Dummer R; Burg G Schweiz Med Wochenschr; 1997 Feb; 127(8):311-20. PubMed ID: 9157537 [TBL] [Abstract][Full Text] [Related]
6. Mycosis fungoides and the Sézary syndrome. Kim YH; Hoppe RT Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085 [TBL] [Abstract][Full Text] [Related]
7. A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome. Thomas BR; Whittaker S Skin Therapy Lett; 2012 Dec; 17(10):5-9. PubMed ID: 23223768 [TBL] [Abstract][Full Text] [Related]
8. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Marolleau JP; Baccard M; Flageul B; Rybojad M; Laroche L; Vérola O; Brandely M; Morel P; Gisselbrecht C Arch Dermatol; 1995 May; 131(5):574-9. PubMed ID: 7741545 [TBL] [Abstract][Full Text] [Related]
9. Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia. Foon KA; Bunn PA Semin Oncol; 1986 Dec; 13(4 Suppl 5):35-9. PubMed ID: 3541217 [TBL] [Abstract][Full Text] [Related]
10. Combined modality therapy with electron-beam irradiation and systemic chemotherapy for cutaneous T-cell lymphomas. Bunn PA; Fischmann AB; Schechter GP; Kumar PP; Ihde DC; Cohen MH; Fossieck BE; Gazdar AF; Matthews MJ; Eddy JL; Minna JD Cancer Treat Rep; 1979 Apr; 63(4):713-7. PubMed ID: 109208 [No Abstract] [Full Text] [Related]
11. Antithymocyte globulin in the management of cutaneous T cell lymphoma. Edelson RL; Raafat J; Berger CL; Grossman M; Troyer C; Hardy M Cancer Treat Rep; 1979 Apr; 63(4):675-80. PubMed ID: 312698 [TBL] [Abstract][Full Text] [Related]
12. Therapy of cutaneous lymphoma--current practice and future developments. Dummer R; Kempf W; Hess Schmid M; Häffner A; Burg G Onkologie; 2003 Aug; 26(4):366-72. PubMed ID: 12972705 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Whittaker SJ; Foss FM Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192 [TBL] [Abstract][Full Text] [Related]
15. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Bunn PA; Lamberg SI Cancer Treat Rep; 1979 Apr; 63(4):725-8. PubMed ID: 445521 [No Abstract] [Full Text] [Related]
16. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas. Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809 [TBL] [Abstract][Full Text] [Related]
17. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers. Hughes CF; Newland K; McCormack C; Lade S; Prince HM Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337 [TBL] [Abstract][Full Text] [Related]